PMID- 38541079
OWN - NLM
STAT- MEDLINE
DCOM- 20240329
LR  - 20240330
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 60
IP  - 3
DP  - 2024 Feb 21
TI  - Evaluation of the Levels of Selected Cytokines and Their Possible Influence on 
      the Development of Cardiovascular and Pulmonary Complications in Patients after 
      COVID-19.
LID - 10.3390/medicina60030353 [doi]
LID - 353
AB  - Background and Objectives: The aim of this study was to evaluate the levels of 
      selected cytokines and their possible influence on the development of 
      cardiovascular and pulmonary complications in patients hospitalized at the 
      Silesian Centre for Heart Disease in Zabrze after having undergone COVID-19. 
      Materials and methods: The study included 76 randomly selected patients from the 
      SILCOVID-19 database. The median time from symptom onset to the study visit was 
      102 (86-118) days. The median age of the study group was 53 (44-60) years. Assays 
      of a panel of 30 cytokines were carried out in the serum of patients on a 
      Luminex100 platform using the Milliplex MAP kit from Merck KGaA Germany. Results: 
      There were no statistically significant differences in most of the cytokines 
      analyzed between patients with confirmed or excluded lung lesions or cardiac 
      abnormalities. Additionally, no statistically significant differences in cytokine 
      concentrations according to gender, age, comorbidity of diabetes, renal disease, 
      hypertension, increased risk of thrombotic disease, or psychological disorders 
      were demonstrated. There were high concentrations of cytokines such as 
      platelet-derived growth actor-AA (PDGF-AA), monocyte chemoattractant protein-1 
      (MCP-1), monokine-induced gamma interferon (MIG), and vascular endothelial growth 
      factor-A (VEGF-A). Conclusions: No direct impact of the dependencies between a 
      panel of cytokines and the incidence of cardiovascular and pulmonary 
      complications in patients hospitalized at the Silesian Centre for Heart Disease 
      in Zabrze after having undergone COVID-19 was demonstrated. The demonstration of 
      high levels of certain cytokines (PDGF-AA, VEGF, MIG, and IP10) that are of 
      significance in the development of many lung diseases, as well as cytokines 
      (MCP-1) that influence the aetiopathogenesis of cardiovascular diseases seems to 
      be highly concerning in COVID-19 survivors. This group of patients should receive 
      further monitoring of these cytokine levels and diagnostic imaging in order to 
      detect more severe abnormalities as early as possible and administer appropriate 
      therapy.
FAU - Stanjek-Cichoracka, Anita
AU  - Stanjek-Cichoracka A
AD  - Department of Biophysics, Faculty of Pharmaceutical Sciences in Sosnowiec, 
      Medical University of Silesia in Katowice, Jednosci 8, 41-200 Sosnowiec, Poland.
AD  - Laboratory of Transplant Immunology, Silesian Centre for Heart Diseases, 41-800 
      Zabrze, Poland.
FAU - Niedziela, Jacek T
AU  - Niedziela JT
AD  - 3rd Department of Cardiology, Silesian Center for Heart Disease, 41-800 Zabrze, 
      Poland.
AD  - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical 
      University of Silesia, 40-752 Katowice, Poland.
FAU - Laszewska, Anna
AU  - Laszewska A
AD  - Laboratory of Transplant Immunology, Silesian Centre for Heart Diseases, 41-800 
      Zabrze, Poland.
FAU - Medrala, Zofia
AU  - Medrala Z
AD  - 3rd Department of Cardiology, Silesian Center for Heart Disease, 41-800 Zabrze, 
      Poland.
FAU - Nowowiejska-Wiewiora, Alicja
AU  - Nowowiejska-Wiewiora A
AD  - 3rd Department of Cardiology, Silesian Center for Heart Disease, 41-800 Zabrze, 
      Poland.
FAU - Kaczmarski, Jacek
AU  - Kaczmarski J
AD  - Department of Laboratory Diagnostics of Environmental and Civilization Diseases, 
      Section of Coagulation Disorders, Silesian Center for Heart Disease, 41-800 
      Zabrze, Poland.
FAU - Grzanka, Alicja
AU  - Grzanka A
AD  - Department of Allergology, Faculty of Medical Sciences in Zabrze, Medical 
      University of Silesia, 40-752 Katowice, Poland.
FAU - Gasior, Mariusz
AU  - Gasior M
AD  - 3rd Department of Cardiology, Silesian Center for Heart Disease, 41-800 Zabrze, 
      Poland.
AD  - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical 
      University of Silesia, 40-752 Katowice, Poland.
LA  - eng
GR  - PCN-1-222/N/2/K/Medical Univercity of Silesia/
PT  - Journal Article
DEP - 20240221
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Cytokines)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - Cytokines
MH  - Vascular Endothelial Growth Factor A
MH  - *COVID-19/complications
MH  - *Heart Diseases/etiology
MH  - Germany
PMC - PMC10972488
OTO - NOTNLM
OT  - COVID-19
OT  - Luminex
OT  - cardiovascular and pulmonary complications
OT  - cytokines
COIS- The authors declare no conflicts of interest.
EDAT- 2024/03/28 06:46
MHDA- 2024/03/29 06:46
PMCR- 2024/02/21
CRDT- 2024/03/28 01:11
PHST- 2024/01/18 00:00 [received]
PHST- 2024/02/11 00:00 [revised]
PHST- 2024/02/19 00:00 [accepted]
PHST- 2024/03/29 06:46 [medline]
PHST- 2024/03/28 06:46 [pubmed]
PHST- 2024/03/28 01:11 [entrez]
PHST- 2024/02/21 00:00 [pmc-release]
AID - medicina60030353 [pii]
AID - medicina-60-00353 [pii]
AID - 10.3390/medicina60030353 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2024 Feb 21;60(3):353. doi: 10.3390/medicina60030353.